Guideline for the application of chromosomal microarray analysis in prenatal diagnosis (2023).
10.3760/cma.j.cn112141-20230327-00146
- Collective Name:Prenatal Screening and Diagnosis Group;Birth Defect Prevention and Control Professional Committee
- Publication Type:Journal Article
- MeSH:
Female;
Humans;
Pregnancy;
Asian People;
Chromosome Aberrations;
Chromosome Deletion;
Chromosome Duplication/genetics*;
DNA Copy Number Variations/genetics*;
Fetal Diseases/genetics*;
Genetic Counseling;
Microarray Analysis;
Prenatal Care;
Prenatal Diagnosis;
Practice Guidelines as Topic
- From:
Chinese Journal of Obstetrics and Gynecology
2023;58(8):565-575
- CountryChina
- Language:Chinese
-
Abstract:
After the promulgation of the first edition of expert consensus on the application of chromosomal microarray analysis (CMA) technology in prenatal diagnosis in 2014, after 8 years of clinical and technical development, CMA technology has become a first-line diagnosis technology for fetal chromosome copy number deletion or duplication abnormalities, and is widely used in the field of prenatal diagnosis in China. However, with the development of the industry and the accumulation of experience in case diagnosis, the application of CMA technology in many important aspects of prenatal diagnosis, such as clinical diagnosis testimony, data analysis and genetic counseling before and after testing, needs to be further standardized and improved, so as to make the application of CMA technology more in line with clinical needs. The revision of the guideline was led by the National Prenatal Diagnostic Technical Expert Group, and several prenatal diagnostic institutions such as Peking Union Medical College Hospital were commissioned to write, discuss and revise the first draft, which was discussed and reviewed by all the experts of the National Prenatal Diagnostic Technical Expert Group, and was finally formed after extensive review and revision. This guideline is aimed at the important aspects of the application of CMA technology in prenatal diagnosis and clinical diagnosis, from the clinical application of evidence, test quality control, data analysis and interpretation, diagnosis report writing, genetic counseling before and after testing and other work specifications are elaborated and introduced in detail. It fully reflects the integrated experience, professional thinking and guidance of the current Chinese expert team on the prenatal diagnosis application of CMA technology. The compilation of the guideline for the application of CMA technology in prenatal diagnosis will strive to promote the standardization and advancement of prenatal diagnosis of fetal chromosome diseases in China.
